The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs
Five electronic databases were searched for eligible records. Outcomes were presented and analyzed according to the objective response rate (ORR), progression-free survival (PFS) rate, and overall survival (OS) rate. Five records involving 2,024 participants were included in the study. The pooled an...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2021/8960315 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555238098206720 |
|---|---|
| author | Hongqiong Yang Yaojun Zhou Liangzhi Wang Tianyi Gu Mengjia Lv Jinling Sun Chao Tu Junbo He |
| author_facet | Hongqiong Yang Yaojun Zhou Liangzhi Wang Tianyi Gu Mengjia Lv Jinling Sun Chao Tu Junbo He |
| author_sort | Hongqiong Yang |
| collection | DOAJ |
| description | Five electronic databases were searched for eligible records. Outcomes were presented and analyzed according to the objective response rate (ORR), progression-free survival (PFS) rate, and overall survival (OS) rate. Five records involving 2,024 participants were included in the study. The pooled analysis of OS and PFS were longer with ramucirumab (RAM) therapy than without RAM for OS (odds ratio OR=0.90, 95% confidence interval CI=0.82–1.00, p=0.05) and PFS (OR=0.74, 95%CI=0.57–0.96, p=0.02). Moreover, compared with the current first-line chemotherapy, the OS (OR=0.93, 95%CI=0.83–1.04, p=0.19) and PFS (OR=0.82, 95%CI=0.64–1.06, p=0.13) results were not significantly higher with RAM. The ORRs of the patients in the RAM therapy groups were significantly higher than those in the groups without RAM (OR=1.40, 95%CI=1.14–1.73, p=0.001). |
| format | Article |
| id | doaj-art-53665f51cc41439884fdccaacb40f147 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-53665f51cc41439884fdccaacb40f1472025-02-03T05:49:16ZengWileyGastroenterology Research and Practice1687-61211687-630X2021-01-01202110.1155/2021/89603158960315The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTsHongqiong Yang0Yaojun Zhou1Liangzhi Wang2Tianyi Gu3Mengjia Lv4Jinling Sun5Chao Tu6Junbo He7Department of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaDepartment of Surgical Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaDepartment of General Practice, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaFive electronic databases were searched for eligible records. Outcomes were presented and analyzed according to the objective response rate (ORR), progression-free survival (PFS) rate, and overall survival (OS) rate. Five records involving 2,024 participants were included in the study. The pooled analysis of OS and PFS were longer with ramucirumab (RAM) therapy than without RAM for OS (odds ratio OR=0.90, 95% confidence interval CI=0.82–1.00, p=0.05) and PFS (OR=0.74, 95%CI=0.57–0.96, p=0.02). Moreover, compared with the current first-line chemotherapy, the OS (OR=0.93, 95%CI=0.83–1.04, p=0.19) and PFS (OR=0.82, 95%CI=0.64–1.06, p=0.13) results were not significantly higher with RAM. The ORRs of the patients in the RAM therapy groups were significantly higher than those in the groups without RAM (OR=1.40, 95%CI=1.14–1.73, p=0.001).http://dx.doi.org/10.1155/2021/8960315 |
| spellingShingle | Hongqiong Yang Yaojun Zhou Liangzhi Wang Tianyi Gu Mengjia Lv Jinling Sun Chao Tu Junbo He The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs Gastroenterology Research and Practice |
| title | The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs |
| title_full | The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs |
| title_fullStr | The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs |
| title_full_unstemmed | The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs |
| title_short | The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs |
| title_sort | efficacy of ramucirumab in the treatment of gastric or gastroesophageal junction cancer a meta analysis of rcts |
| url | http://dx.doi.org/10.1155/2021/8960315 |
| work_keys_str_mv | AT hongqiongyang theefficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT yaojunzhou theefficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT liangzhiwang theefficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT tianyigu theefficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT mengjialv theefficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT jinlingsun theefficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT chaotu theefficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT junbohe theefficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT hongqiongyang efficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT yaojunzhou efficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT liangzhiwang efficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT tianyigu efficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT mengjialv efficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT jinlingsun efficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT chaotu efficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts AT junbohe efficacyoframucirumabinthetreatmentofgastricorgastroesophagealjunctioncancerametaanalysisofrcts |